Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Editorial
Nature Reviews Microbiology 4, 565–566 (1 August 2006) | doi:10.1038/nrmicro1482
Influenza pandemic vaccines: how to ensure a low-cost, low-dose option
&
Abstract
Global access to an effective influenza vaccine will be essential in the event of a pandemic. Here, the WHO's Klaus St|[ouml]|hr, Marie-Paule Kieny and David Wood argue that assessing the clinical benefits of low-dose H5N1 vaccines in animal models is crucial to achieving this goal.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
